From: Emerging role of human polyomaviruses 6 and 7 in human cancers
Cancer | Specimen types | Samples n | Method | HPyV6 Positive n (%) | HPyV7 Positive n (%) | Reference |
---|---|---|---|---|---|---|
MM | FFPE | 47 | rt-PCR/Seq. | 2 (4.3) | 2 (4.3) | [25] |
AK | FFPE | 31 | qPCR | 1 (3) | ND | [27] |
AK | FFPE | 92 | Seq. | 4 (4.3) | NA | [69] |
AK | FFPE | 2 | qPCR | ND | 1 (50) | [53] |
VK | FFPE | 4 | qPCR | 3 (75) | 3 (75) | [53] |
BCC | FFPE | 18 | qPCR | 10 (5.5) | ND | [29] |
BCC | FFPE | 41 | qPCR | 3 (7) | ND | [27] |
BCC | FFPE | 50 | rt-PCR/Seq. | 1 (2) | 2 (4) | [25] |
BCC | FFPE | 109 | PCR/Seq./FISH | 23 (21.1) | NA | [68] |
SCC | FFPE | 8 | qPCR | 1 (12) | ND | [27] |
SCC | FFPE | 21 | qPCR | 8 (38) | ND | [29] |
SCC | FFPE | 52 | qPCR | 2 (4) | ND | [27] |
SCC | FFPE | 86 | PCR/Seq./FISH | 8 (9.3) | NA | [68] |
SCC | FFPE | 63 | rt-PCR/Seq. | 2 (3.2) | 1 (1.6) | [25] |
SCC IN CLL cases who had BMT | FFPE | 3 | Bead-based multiplex PCR | 1 (33.3) | ND | [28] |
SCC | FFPE | 11 | qPCR | 4 (36.4) | 6 (54.5) | [53] |
SCC | FFPE | 17 (6 patients) | rt-PCR/IHC | 17 (100) | 17 (100) | [26] |
KA | FFPE | 42 | qPCR | 2 (5) | ND | [27] |
KA | FFPE | 59 | PCR/Seq/FISH | 25 (42.3) | NA | [68] |
TB | FFPE | 45 | PCR/Seq | 10 (22.2) | NA | [68] |
MCC | FFPE | 20 | qPCR | 2 (10) | ND | [29] |
MCC | FFPE | 28 | rt-PCR | 1 (3.5) | 1 (3.5) | [30] |
CTCLs | FFPE | 116 | rt-PCR | 6 (5.20) | 1 (0.90) | [70] |
CTCLs | FF | 71 | rt-PCR | 13 (18.3) | ND | [24] |
CTCLs | FF and FFPE | 35 | rt-PCR | 7 (20) | 3 (8.6) | [71] |
Total | Â | 1072 | Â | 157/1072 (14.6) | 37/681 (5.4) | Â |